Reducing the risk of vascular calcification Innovative therapies reach the clinical end of Phase 2b

In patients with chronic kidney disease, especially end-stage nephropathy, metabolic and hormonal abnormalities lead to inflammation, malnutrition, mineral metabolism abnormalities, anemia and other symptomsThese symptoms can trigger calcium deposition in the patient's cardiovascular system, leading to the onset of cardiovascular diseaseCalcified defense is a serious form of cardiovascular calcificationCalcium deposition can clog small blood vessels in the skin and adipose tissue, leading to very painful and deactivation chronic skin lesionsCalcicification defense occurs in 1-4% of patients who receive dialysis, with a one-year mortality rate of up to 55%Sanifit is one of this year's "Fierce Biotech's 2019 Fierce 15." The company's flagship product, SNF472, is a specific calcification inhibitor with an innovative mechanismThe main component of calcium deposition is hydroxyapatite crystals, and SNF472 prevents crystal spawning and continues to grow by binding to hydroxyapatite crystals that are being produced or already existThis prevents the production of cardiovascular calcificationimage source: Sanifit's websitea total of 274 patients with end-stage kidney disease receiving dialysis received different doses of SNF472 or placebo in a 52-week, randomized double-blind, placebo-controlled international Phase 2b clinical trialThe results showed a significant decrease in the volume of calum calcium deposition in coronary arterial syltos in patients treated with SNF472 compared to the placebo group"These results are the first to show that the ultimate common approach to cardiovascular calcification can improve the risk of cardiovascular disease in patients with end-stage nephropathy," saidSanifit CEO, Joan PerellWe will continue the development of SNF472 to provide patients with end-stage kidney disease on dialysis with innovative treatments for cardiovascular calcificationReferences:sanifit announces that the Phase 2b CaLIPso trial of SNF472 met its primary edity in the slow ing the progression of cardiovascular calcification in patients on hemodialysisRetrieved October 30, 2019, from https:// sanifit Retrieved October 30, 2019, from https://#mechanism-of-action